# Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT07197307** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Universität Münster** · enrollment: 120 (estimated)

## Conditions studied

- Aggressive Diffuse Large B-cell Lymphoma
- High-grade B-cell Lymphoma (HGBL)
- Follicular Lymphoma (FL) Grade 3B

## Interventions

- **DRUG:** Loncastuximab Tesirine and Epcoritamab

## Key facts

- **NCT ID:** NCT07197307
- **Lead sponsor:** Universität Münster
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2030-01-15
- **Final completion:** 2030-01-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07197307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07197307, "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07197307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*